A Long-term Follow-up of the HIV-NAT Cohort

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description expanded, about 9 words
    • Publications: details revised at 19 of 21 entries
    • Eligibility criteria expanded, about 4 words
  2. 4 versions Re-verified since Sep 7, 2020, no change to tracked fieldsv13-v16
  3. Primary and study completion dates: Dec 2020 to Dec 2030v12
  4. 3 versions Re-verified since Feb 18, 2016, no change to tracked fieldsv9-v11
  5. Enrollment target: 2000 to 10000
    • Publications: 17 to 21
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Primary completion date: Dec 2020
    • Study completion date: Dec 2012 to Dec 2020
    v7
  2. Re-verified, no change to tracked fieldsv6
  3. Study Identification, Study Statusv5
  4. 2 versions Re-verified since Feb 15, 2008, no change to tracked fieldsv3-v4
  5. Enrollment target: 2000
    • Study completion date: Dec 2012
    • Study description expanded, about 139 words
    • Publications: 7 to 17
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
With HIV/AIDS increasingly considered a chronic disease, 24-, or 48-week data from antiretroviral studies are no longer sufficient. Only with long-term follow-up and outcome data will shed some much-needed light on the answers of questions that have stumped us for several years. Data from a large observational cohort of patients treated with combination antiretroviral therapy will provide further insights into the long-term safety and durability of various antiretroviral therapeutic approached, the efficacy of HIV viral load and CD4 cell counts as predictors of disease progression and mortality, and the importance of adherence.
Trial Details
NCT Number NCT00411983
Lead Sponsor The HIV Netherlands Australia Thailand Research Collaboration
Conditions
(from sponsor)		 HIV Infections
Related terms HIV Infections
Enrollment 10,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov